Answers are grounded in this paper and cite their sources.
Introduction Breast cancer is a leading cause of cancer-related mortality among women. Quercetin (Que), a natural flavonoid, is a promising candidate owing to its multitargeted anticancer activity. However, the preclinical evidence for Que and its nanoformulations (Que NFs) remains insufficiently synthesized. This systematic review and meta-analysis aimed to evaluate the antitumor efficacy, safety, and underlying mechanisms of Que and Que NFs in preclinical breast cancer models, and to quantitatively compare free Que with Que NFs. Methods The protocol was registered on PROSPERO (CRD420251116713). Relevant studies published up to 8 October 2026 were identified from six electronic databases (PubMed, Web of Science, Embase, Cochrane Library, WanFang Data, and China National Knowledge Infrastructure). Controlled preclinical animal studies evaluating Que or Que NFs in breast cancer models were included. Methodological quality was assessed using SYRCLE’s risk of bias tool, and meta-analyses were conducted using RevMan 5.4 and Stata 12.0. Outcomes included tumor-related efficacy and safety parameters. Mechanistic findings were summarized descriptively. Results A total of 45 articles comprising 47 independent in vivo experiments were included. Pooled evidence indicated that both Que and Que NFs significantly reduced tumor volume, tumor weight, and lung metastatic nodule counts in vivo . Direct comparisons indicated greater reductions in these outcomes with Que NFs than with free Que, including in matched-regimen analyses. Exploratory combination analyses showed reductions in tumor volume for both Que- and Que NF-based combinations, whereas a significant reduction in tumor weight was observed only for Que NF-based combinations relative to corresponding comparator treatments. Safety analyses indicated elevated ALT levels in healthy animals treated with free Que and lower platelet counts in tumor-bearing animals receiving free Que. Reported mechanisms involved apoptosis, cell cycle arrest, epithelial-mesenchymal transition inhibition, and tumor immune microenvironment modulation. Discussion Despite substantial heterogeneity, this meta-analysis provides a quantitative synthesis of the available preclinical evidence on Que and Que NFs in breast cancer animal models, highlighting their observed antitumor effects and important evidence gaps for future research. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251116713 , identifier CRD420251116713.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: